ZyVersa Therapeutics (ZVSA) News Today $0.73 -0.04 (-4.92%) Closing price 03/25/2025 03:35 PM EasternExtended Trading$0.72 -0.01 (-1.09%) As of 03/25/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period ZyVersa Therapeutics (ZVSA) Expected to Announce Earnings on MondayMarch 22, 2025 | americanbankingnews.comZyVersa Therapeutics announces publication of data on inflammasome inhibitionMarch 19, 2025 | markets.businessinsider.comCritical Contrast: ZyVersa Therapeutics (NASDAQ:ZVSA) and NuCana (NASDAQ:NCNA)March 19, 2025 | americanbankingnews.comZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model StudyMarch 18, 2025 | globenewswire.comZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer's Disease Mouse ModelMarch 12, 2025 | globenewswire.comZyVersa Therapeutics Advances Cardio-Metabolic Treatment With IC 100 In Obese Animal ModelMarch 8, 2025 | nasdaq.comZyVersa Therapeutics prices 2.1M shares at 95c in private placementMarch 6, 2025 | markets.businessinsider.comZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The MarketMarch 6, 2025 | globenewswire.comZyVersa Therapeutics highlights data on NLRP3 inflammasome inhibitionMarch 5, 2025 | markets.businessinsider.comZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 DiabetesMarch 5, 2025 | globenewswire.comZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San FranciscoDecember 19, 2024 | markets.businessinsider.comZyVersa Therapeutics' CEO, Stephen C. Glover, to Attend JPM's Healthcare Conference 2025 in San FranciscoDecember 18, 2024 | globenewswire.comOTC Markets Hosts Virtual Investor Presentation with Stephen Glover, CEO of ZyVersa Therapeutics, Inc., with Brad Sorensen, Senior Analyst at Zacks SCRNovember 21, 2024 | msn.comZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical TrialNovember 20, 2024 | globenewswire.comZyVersa Therapeutics Reports Q3 Progress and OutlookNovember 16, 2024 | markets.businessinsider.comZyVersa Therapeutics reports Q3 EPS ($2.43) vs ($30.18) last yearNovember 15, 2024 | markets.businessinsider.comZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business UpdateNovember 14, 2024 | globenewswire.comZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 DiabetesNovember 5, 2024 | globenewswire.comZyVersa Therapeutics’ Shareholder Approvals and Director ElectionsOctober 31, 2024 | markets.businessinsider.comZyVersa highlights review article on inflammasome-induced inflammationOctober 30, 2024 | markets.businessinsider.comZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss DrugsOctober 29, 2024 | globenewswire.comZyVersa Therapeutics (NASDAQ:ZVSA) Stock, Short Interest ReportOctober 23, 2024 | benzinga.comZyVersa Therapeutics announces publication of data on obesity, neuroinflammationOctober 23, 2024 | markets.businessinsider.comZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative DiseasesOctober 22, 2024 | globenewswire.comZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine MonthsOctober 17, 2024 | globenewswire.comZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome InhibitorsOctober 15, 2024 | globenewswire.comZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic ComplicationsOctober 7, 2024 | globenewswire.comGenenta Science S.p.A. (K5F.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comZVSA Stock Earnings: ZyVersa Therapeutics Beats EPS for Q2 2024August 9, 2024 | investorplace.comZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business UpdateAugust 9, 2024 | globenewswire.comZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic InflammationAugust 7, 2024 | globenewswire.comZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older AdultsJuly 29, 2024 | globenewswire.comZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100July 25, 2024 | globenewswire.comZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal ModelJuly 18, 2024 | globenewswire.comZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C.July 9, 2024 | globenewswire.comZyVersa Therapeutics Stock (NASDAQ:ZVSA), Earnings Estimates, EPS, and RevenueMay 17, 2024 | benzinga.comZVSA Stock Earnings: ZyVersa Therapeutics Misses EPS for Q1 2024May 16, 2024 | investorplace.comZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business UpdateMay 15, 2024 | globenewswire.comZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International ConventionMay 14, 2024 | globenewswire.comWhat's Going On With ZyVersa Stock?April 29, 2024 | msn.comTrading was temporarily halted for "ZVSA" at 10:04 AM with a stated reason of "LULD pause."April 29, 2024 | marketbeat.comZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s DiseaseApril 29, 2024 | finance.yahoo.comZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer's DiseaseApril 29, 2024 | globenewswire.comTrading was temporarily halted for "ZVSA" at 07:04 PM with a stated reason of "News pending."April 26, 2024 | marketbeat.comZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with DiabetesApril 4, 2024 | globenewswire.comZyVersa Therapeutics Stock (NASDAQ:ZVSA), Quotes and News SummaryApril 3, 2024 | benzinga.comBuy Rating Affirmed: ZyVersa Therapeutics’ Promising Pipeline and Strategic AdvancementsMarch 27, 2024 | markets.businessinsider.comZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateMarch 25, 2024 | globenewswire.comZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney DiseaseMarch 18, 2024 | globenewswire.comZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024March 14, 2024 | finance.yahoo.com Remove Ads Get ZyVersa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVSA and its competitors with MarketBeat's FREE daily newsletter. Email Address ZVSA Media Mentions By Week ZVSA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ZVSA News Sentiment▼0.000.77▲Average Medical News Sentiment ZVSA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ZVSA Articles This Week▼20▲ZVSA Articles Average Week Remove Ads Get ZyVersa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVSA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BTAI News ONVO News BGXX News OMGA News CYCN News SNOA News NKGN News GTBP News SNGX News ALZN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ZVSA) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZyVersa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZyVersa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
